Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on EquityReturn on Sales

Innate Pharma (IPHA) Return on Assets (2023 - 2024)

Historic Return on Assets for Innate Pharma (IPHA) over the last 6 years, with Q2 2025 value amounting to 0.1%.

  • Innate Pharma's Return on Assets fell 900.0% to 0.1% in Q2 2025 from the same period last year, while for Jun 2025 it was 0.1%, marking a year-over-year decrease of 900.0%. This contributed to the annual value of 0.0% for FY2022, which is 300.0% up from last year.
  • As of Q2 2025, Innate Pharma's Return on Assets stood at 0.1%, which was down 900.0% from 0.08% recorded in Q4 2024.
  • Innate Pharma's 5-year Return on Assets high stood at 0.0% for Q2 2021, and its period low was 0.1% during Q2 2025.
  • Over the past 5 years, Innate Pharma's median Return on Assets value was 0.01% (recorded in 2024), while the average stood at 0.03%.
  • In the last 5 years, Innate Pharma's Return on Assets skyrocketed by 400bps in 2024 and then plummeted by -900bps in 2025.
  • Quarter analysis of 5 years shows Innate Pharma's Return on Assets stood at 0.0% in 2021, then tumbled by -11148bps to 0.04% in 2022, then soared by 80bps to 0.01% in 2023, then crashed by -888bps to 0.08% in 2024, then fell by -16bps to 0.1% in 2025.
  • Its Return on Assets stands at 0.1% for Q2 2025, versus 0.08% for Q4 2024 and 0.01% for Q2 2024.